KZR-616 demonstrates improvement across all exploratory efficacy measures and is observed to be well-tolerated up to 75 mg subcutaneously once weekly for 13 weeks. The MISSION Phase 1b data support the development of KZR-616 in multiple immune-mediated diseases. Conference call and webcast to be held at 4:30pm ET. SOUTH SAN… Read More..
FRAMINGHAM, Mass., June 02, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, today announced that it will be presented virtually at the upcoming LD Micro Invitational XI event. Chief Executive Officer, Terrence W. Norchi, MD, and… Read More..
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced the appointment of Micki Klearman, M.D. to its Board of Directors. “Micki’s addition to the board is instrumental as we continue to evaluate the broad… Read More..